First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel. Background: ARN-509 is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results